A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis.

This is a prospective, randomized, double-blind, placebo-controlled study to investigate the safety, PK, and PD of CSL312 in patients with IPF. Approximately 80 patients with a confirmed diagnosis of IPF will be enrolled and randomized to treatment in a 1:1 ratio; to achieve a total of 70 evaluable subjects by Week 14; 35 subjects in the CSL312 600 mg group and 35 subjects in the placebo group.